HLA-DQ2 (DQA1*05/DQB1*02)

If you have chronic gut trouble, unexplained anemia, low bone density, a close relative with celiac disease, or a child you are trying to protect from years of missed diagnosis, this test answers one specific question. Do you carry the inherited genetic setup that makes celiac disease biologically possible? About 90% of people with celiac disease carry the DQ2.5 version of this gene combination, so a negative result is one of the most powerful ways in medicine to essentially close the door on celiac disease as an explanation for your symptoms.

This is a one-time genetic test. Your result will not change over your lifetime. What changes is how you use it: to decide whether to keep watching for celiac disease with periodic blood testing, whether to test your children, or whether you can stop worrying about celiac disease entirely and look elsewhere for answers.

What This Test Actually Measures

HLA-DQ2 (human leukocyte antigen DQ2) refers to a receptor on the surface of certain immune cells. That receptor is built from two protein pieces: an alpha piece made from the DQA105 gene and a beta piece made from the DQB102 gene. When both pieces are present, they snap together to form the full DQ2.5 receptor. This receptor is unusually good at grabbing fragments of gluten and showing them to the immune system, which is why it is so tightly tied to celiac disease.

The test reports whether you carry these two alleles and, when possible, whether you carry one copy or two. The pieces can be inherited on the same chromosome (called the cis pattern) or on separate chromosomes from each parent (the trans pattern). Both configurations produce a functional DQ2.5 receptor and both raise celiac risk.

Celiac Disease Risk

HLA-DQ2 is the single strongest inherited risk factor for celiac disease. Around 90% of people with celiac disease carry DQ2.5, and more than 98% carry either DQ2.5, DQ2.2, or DQ8. Fewer than 2% of people with celiac disease lack these types entirely.

Risk goes up with dose. In a pediatric meta-analysis, people carrying DQ2/DQ2 (two full copies of the risk pair) had about 5.4 times the odds of developing celiac disease compared with people carrying no DQ2 or DQ8 alleles. A closely related genotype with two DQB102 alleles plus one DQA105 allele carried nearly identical odds, at about 5.3 times higher. In a large U.S. at-risk cohort of 10,191 people, 28.28% of those who were homozygous for DQ2.5 or carried the DQ2.2/DQ2.5 combination were positive for the endomysial antibody used to screen for celiac disease, compared with 9.09% of those with just one DQ2.5 copy.

But carrying HLA-DQ2 does not mean you will get celiac disease. Roughly 20% to 30% of white populations carry DQ2, and only about 1% of the general population actually develops the disease. In a Danish general-population study, 47.7% of adults carried DQ2 and/or DQ8, and most of them had no diagnosed celiac disease. Think of the gene as loading the possibility, with gluten exposure and other factors pulling the trigger.

Ruling Celiac Disease In vs. Out

The clinical power of this test is asymmetric. A positive result raises risk but cannot confirm celiac disease. A negative result, meaning you carry neither DQ2 nor DQ8, is much more useful: multiple studies show a negative predictive value approaching 100% in individual patients. In the U.S. at-risk cohort, only 0.16% of samples lacking both DQ2 and DQ8 tested positive for celiac antibodies.

That is why HLA-DQ2 testing is most valuable when a celiac diagnosis is unclear: when someone has already started a gluten-free diet before serology could be checked, when the blood tests and biopsy disagree, or when biopsy findings are mild. In those situations, a fully negative HLA result can essentially close the celiac chapter and free you to investigate other causes of your symptoms.

Family History and What It Means for Relatives

Celiac disease clusters in families. In an Indian cohort of first-degree relatives, celiac disease seroprevalence reached 13.3% by blood testing and 10.9% by biopsy, showing how much higher risk is among close family than in the general population. Global meta-analyses report pooled first-degree-relative seroprevalence of about 11% and biopsy-confirmed prevalence of about 7%.

A positive HLA-DQ2 result in a first-degree relative of someone with celiac disease is a signal to enter periodic celiac blood-antibody screening rather than assume you are safe. A negative result in the same setting means routine antibody screening can generally be dropped, because your baseline lifetime risk falls close to that of the general non-carrier population.

Type 1 Diabetes and Autoimmune Overlap

HLA-DQ2 is not exclusive to celiac disease. The DR3-DQ2 haplotype (a group of gene variants inherited together on the same chromosome) is one of the strongest inherited risk factors for type 1 diabetes as well. In a diabetes prevention trial cohort of over 11,000 people with early islet autoimmunity, the DQA105:01-DQB102:01 haplotype was linked to about 19% faster progression to symptomatic type 1 diabetes (hazard ratio 1.19).

The highest type 1 diabetes risk usually comes from carrying DR3-DQ2 together with DR4-DQ8, a combination that carried about 13 times the odds of type 1 diabetes in a Finnish study. HLA-DQ2 alone is a milder signal in that context, but if you already know you have type 1 diabetes or a strong family history of it, a positive DQ2 result adds meaningful context for how closely you and your children should be watched for celiac disease as well.

Other Autoimmune Associations

HLA-DQ2 has also been linked to dermatitis herpetiformis (the skin condition tied to celiac disease), certain neurologic autoimmune syndromes involving anti-GAD65 antibodies, and higher odds of forming antibodies against the drug infliximab used for inflammatory bowel disease. In anti-GAD65 neurologic syndromes, the DQB1*02:01 allele was found in about 41% of patients versus about 15% of controls, corresponding to roughly 3.96 times the odds. For infliximab immunogenicity, DQ2 haplotypes were linked to about 3.18 times higher odds of developing anti-drug antibodies.

These associations are real but weaker and more context-dependent than the celiac link. HLA-DQ2 is best thought of primarily as a celiac risk marker, with autoimmune overlap as a secondary consideration in specific settings.

Reconciling the Paradox of a Common Risk Gene

Nearly half of some general populations carry DQ2 or DQ8, yet only about 1% get celiac disease. This is not a contradiction. HLA-DQ2 is best understood as a permission slip, not a verdict. Without the gene, the specific gluten reaction that causes celiac disease cannot happen. With the gene, celiac disease becomes possible but requires additional factors, likely including gluten exposure, gut environment, and other genes, to actually develop. That is why a positive result should never be treated as a diagnosis and a negative result is so powerful for exclusion.

One-Time Result, Lifetime Use

Because HLA-DQ2 is a fixed germline genotype, you never need to repeat this test. What does change over time is your risk of actually developing celiac disease, especially if you carry DQ2. The right cadence is not to retest the gene, but to retest antibodies. If you are DQ2 positive with a family history or ongoing gut symptoms, most experts suggest periodic tissue transglutaminase IgA (tTG-IgA) blood testing, especially in childhood and whenever new symptoms appear. If your antibody levels ever rise, that is when you act, not when the gene changes.

When the Result Can Be Misleading

A few situations can distort what looks like a clean answer.

• Incomplete panels: some labs test only for the classic DQ2.5 heterodimer and miss DQ2.2 (DQA102/DQB102), which is a smaller but real celiac risk allele. A report calling you DQ2-negative when DQ2.2 was not tested can wrongly reassure you.
• Half-DQ2 reports: some reports say DQ2 positive when only the alpha (DQA105) or only the beta (DQB102) piece is present. Neither half alone is the same as full DQ2.5, and a partial hit carries much lower risk than the full pair.
• Rare non-DQ2 celiac disease: a small share of confirmed celiac patients, about 3% in an older Spanish meta-analysis and closer to 1% in more recent Spanish pediatric data, do not carry DQ2.5 or DQ8. A negative HLA test is very reassuring but not literally absolute if clinical suspicion is high.
• Ancestry differences: the specific allele mixes and their risk levels have been mapped mostly in European and North American populations. Interpretation in other ancestries may differ, and rare local variants can influence results.

What to Do With an Out-of-Pattern Result

If your result is negative for DQ2 and DQ8, and the lab specifically tested for both DQ2.5 and DQ2.2 configurations, you can generally consider inherited celiac risk essentially closed and shift focus to non-celiac causes of your symptoms. If your result is positive, especially with a double dose of DQB1*02, the right next steps are ongoing tTG-IgA antibody screening on a regular schedule, a conversation about testing biological children and siblings, and lower thresholds for celiac blood testing whenever new unexplained gut, skin, bone, or fatigue symptoms appear.

If you are already on a gluten-free diet and were never formally tested, a positive HLA result plus symptoms that returned during gluten exposure is often the trigger for a formal celiac workup by a gastroenterologist. If you have type 1 diabetes or a first-degree relative with it, a positive DQ2 result is worth showing to your endocrinologist so celiac screening can be built into your ongoing diabetes care.

Common Traps in Interpretation

Two mistakes recur even among clinicians. The first is treating positive HLA-DQ2 as a celiac diagnosis. In one survey, about half of physicians incorrectly believed carrying HLA-DQ2 or DQ8 causes celiac disease in all carriers, and 36% would start a celiac workup with genetic testing rather than antibody testing. Current evidence is clear: the gene is necessary but not sufficient, and positive predictive value is low. The second mistake is treating a negative or partial result as absolute without checking exactly which alleles were tested. Ask your lab or clinician which specific alleles the assay covers, and whether DQ2.2 is included.